AN1 Stock Overview
Anagenics Limited, a consumer health company, develops, manufactures, and markets anti-aging products for hair, skin, and wellbeing in Australia, the United States, China, and Japan.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.021|
|52 Week High||AU$0.073|
|52 Week Low||AU$0.019|
|1 Month Change||-40.00%|
|3 Month Change||-53.33%|
|1 Year Change||-65.00%|
|3 Year Change||-88.65%|
|5 Year Change||-95.80%|
|Change since IPO||-99.46%|
Recent News & Updates
|AN1||AU Personal Products||AU Market|
Return vs Industry: AN1 underperformed the Australian Personal Products industry which returned -33.6% over the past year.
Return vs Market: AN1 underperformed the Australian Market which returned -9.6% over the past year.
|AN1 Average Weekly Movement||12.6%|
|Personal Products Industry Average Movement||9.3%|
|Market Average Movement||9.8%|
|10% most volatile stocks in AU Market||16.5%|
|10% least volatile stocks in AU Market||4.3%|
Stable Share Price: AN1 is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: AN1's weekly volatility (13%) has been stable over the past year.
About the Company
Anagenics Limited, a consumer health company, develops, manufactures, and markets anti-aging products for hair, skin, and wellbeing in Australia, the United States, China, and Japan. It develops and sales FGF5 inhibitor hair health and hair growth products under the evolis, evolis Professional, Lexilis Hybrid, Jo-Ju RED, and Lexilis BLACK brands. In addition, the company markets its products through retailers and wholesalers, as well as through a direct-to-consumer, e-commerce platform.
Anagenics Fundamentals Summary
|AN1 fundamental statistics|
Is AN1 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AN1 income statement (TTM)|
|Cost of Revenue||AU$2.95m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.015|
|Net Profit Margin||-45.53%|
How did AN1 perform over the long term?See historical performance and comparison
Is AN1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AN1?
Other financial metrics that can be useful for relative valuation.
|What is AN1's n/a Ratio?|
Price to Sales Ratio vs Peers
How does AN1's PS Ratio compare to its peers?
|AN1 PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
HCT Holista Colltech
BIO Biome Australia
EXL Elixinol Wellness
Price-To-Sales vs Peers: AN1 is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (2.4x).
Price to Earnings Ratio vs Industry
How does AN1's PE Ratio compare vs other companies in the Global Personal Products Industry?
Price-To-Sales vs Industry: AN1 is good value based on its Price-To-Sales Ratio (0.6x) compared to the Global Personal Products industry average (1.8x)
Price to Sales Ratio vs Fair Ratio
What is AN1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||0.6x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate AN1's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of AN1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate AN1's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate AN1's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AN1's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Anagenics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Household industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Anagenics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
How has Anagenics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AN1 is currently unprofitable.
Growing Profit Margin: AN1 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AN1 is unprofitable, but has reduced losses over the past 5 years at a rate of 0.1% per year.
Accelerating Growth: Unable to compare AN1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AN1 is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (14.3%).
Return on Equity
High ROE: AN1 has a negative Return on Equity (-30.65%), as it is currently unprofitable.
Discover strong past performing companies
How is Anagenics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: AN1's short term assets (A$11.4M) exceed its short term liabilities (A$5.0M).
Long Term Liabilities: AN1's short term assets (A$11.4M) exceed its long term liabilities (A$1.4M).
Debt to Equity History and Analysis
Debt Level: AN1 has more cash than its total debt.
Reducing Debt: AN1's debt to equity ratio has reduced from 17.1% to 15.9% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AN1 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AN1 has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 3.9% each year.
Discover healthy companies
What is Anagenics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AN1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AN1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AN1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AN1's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AN1 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Matthew Dudek serves as Acting Chief Executive Officer at Anagenics Limited (formerly known as Cellmid Limited) since February 28, 2022 and served as its Group Financial Controller since March 2021 unt...
Experienced Management: AN1's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.9%.
Anagenics Limited's employee growth, exchange listings and data sources
- Name: Anagenics Limited
- Ticker: AN1
- Exchange: ASX
- Founded: 2004
- Industry: Personal Products
- Sector: Household
- Implied Market Cap: AU$4.199m
- Shares outstanding: 221.02m
- Website: https://www.anagenics.com
- Anagenics Limited
- 55 Clarence Street
- Suite 204
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/28 00:00|
|End of Day Share Price||2022/06/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.